EVOLTRA
-
Opinions on drugs -
Posted on
Aug 01 2008
- Updated on
Jan 12 2010
Reason for request
Inclusion on the list of medicines approved for use by hospitals
-
Clinical Benefit
Substantial |
The actual benefit of this medicinal product is substantial. |
Clinical Added Value
important |
Despite the methodological limitations of this study, the Committee considers that EVOLTRA brings a significant improvement to the actual benefit (IAB II) in the treatment of acute lymphoblastic leukaemia in relapsed or refractory children after at least two lines of treatment. Because in this population, for which there is no therapeutic alternative able to promise a lasting response, EVOLTRA can for some patients facilitate access to an allograft. |
Contact Us
Évaluation des médicaments